病例PFS 近 3 年，赛沃替尼单药治疗 MET ex14 跳突 NSCLC 实现持续 PR

导语：长治久安，赛沃替尼助力 MET ex14 跳突肺癌患者拥抱正常生活。

内容策划：方程

项目审核：杨静

参考文献：

[1]Spitaleri G, et al. MET in Non-Small-Cell Lung Cancer （NSCLC）: Cross 'a Long and Winding Road' Looking for a Target. Cancers （Basel）. 2023;15（19）:4779.

[2]Awad MM, et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016;34（7）:721-30.

[3]Schoenfeld AJ, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31（5）:599-608.

[4]Negrao MV, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021;9（8）:e002891.

[5]Lu S, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021;9（10）:1154-1164.

[6]张文会, 等. 肺肉瘤样癌的诊疗进展评述. 肿瘤预防与治疗. 2023;36（9）:732-737.

[7]Gong C, et al. MET alterations in advanced pulmonary sarcomatoid carcinoma. Front Oncol. 2022:12:1017026.